We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04149145
Recruitment Status : Not yet recruiting
First Posted : November 4, 2019
Last Update Posted : January 9, 2023
Sponsor:
Information provided by (Responsible Party):
Rebecca Arend, University of Alabama at Birmingham

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : May 2027
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):